dpp4 and glp 1 combination Table 2 from DPP- 4 Inhibitors in the Management of Type 2 Diabetes Mellitus GLP-1 Agonists: Increasing Effective Insulin
Description
This can be OK for some people who may respond well and not need a more potent drug, or those with less body fat to lose
The safety profile was similar to that described in other clinical trials [56]
C.et al (2007b)
Initially approved by the FDA as a treatment for type 2 diabetes, in recent years GLP-1 agonists have become synonymous with weight loss
Yes, if you meet NICE eligibility criteria, typically when triple oral therapy for type 2 diabetes is inadequate and specific BMI or comorbidity thresholds apply
